Industry Articles
Updates about sleep-related diagnostic devices, therapies, products and companies
FDA grants orphan drug status to Lumryz for idiopathic hypersomnia
On June 5, 2025, Avadel Pharmaceuticals announced that the FDA granted orphan drug designation to Lumryz, its extended-release sodium oxybate medication, for the treatment of idiopathic hypersomnia (IH). The FDA’s orphan drug designation provides incentives for drugs and biologics for the treatment of rare [...]
